HYDROXYPROGESTERONE CAPROATE (hydroxyprogesterone caproate) by Aspen Surgical is clinical pharmacology hydroxyprogesterone is a potent, long-acting, progestational steroid ester which transforms proliferative endothelium into secretory endothelium, induces mammary gland duct development, and inhibits the production and/or release of gonadotropic hormone; it also shows slight estrogenic, androgenic, or corticoid effects as well, but should not be relied upon for these effects. Approved for preterm birth.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
Hydroxyprogesterone caproate is a long-acting progestational steroid ester administered via intramuscular injection for the prevention of preterm birth. It transforms proliferative endothelium into secretory endothelium and inhibits gonadotropic hormone release, with peak serum levels appearing 3-7 days after injection.
Pre-launch stage suggests limited current team size with potential for growth upon market entry; early-stage roles in medical affairs and regulatory strategy are most active.
CLINICAL PHARMACOLOGY Hydroxyprogesterone is a potent, long-acting, progestational steroid ester which transforms proliferative endothelium into secretory endothelium, induces mammary gland duct development, and inhibits the production and/or release of gonadotropic hormone; it also shows slight…
Worked on HYDROXYPROGESTERONE CAPROATE at Aspen Surgical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Relationship Between Plasma Concentration of Hydroxyprogesterone Caproate (17-OHPC) and Preterm Birth
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moPre-launch stage offers early-mover advantage for building a specialized commercial team in women's health and obstetrics. Career growth depends heavily on successful market penetration in a competitive, mature progesterone market with modest current spending.